MEDICAL MANAGEMENT OF<i>ASPERGILLUS FLAVUS</i>ENDOCARDITIS

Rao, Kamini; Saha, Vaskar

doi:10.1080/08880010050034382

Cited by 29 publications

(24 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[4][5][6][7][8][9][10][11][12] Patients undergoing HSCT are at risk for the development of endocarditis for several reasons. In-dwelling central venous (Hickman) catheters are routinely utilized and may be left in place for several months.…”

Section: Discussionmentioning

confidence: 99%

“…2,3 Endocarditis has been reported infrequently in the setting of HSCT. A number of case reports and case series have described infectious endocarditis (IE) in HSCT patients [4][5][6] with the largest series involving seven patients. 7 Marantic or nonbacterial thrombotic endocarditis (NBTE) has also been documented in both individual reports 8,9 and larger autopsy series.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation

Kuruvilla

Forrest

Lavoie

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation

Kuruvilla

Forrest

Lavoie

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Amphotericin penetrates poorly into cardiac vegetations but nevertheless should probably be used as adjunctive therapy. High doses (for example, 10 mg/kg/day) of lipid preparations of amphotericin B have been used (252). There is very little or no clinical data on the use of voriconazole, caspofungin, rifampin, or flucytosine in conjunction with amphotericin in this setting.…”

Section: Vol 18 2005 Aspergillus Infections In Transplant Recipientmentioning

confidence: 99%

“…Early surgical intervention with valve replacement is the cornerstone of successful management. Only a small number of patients who received medical therapy alone and survived have been reported (174,252). Amphotericin penetrates poorly into cardiac vegetations but nevertheless should probably be used as adjunctive therapy.…”

Section: Vol 18 2005 Aspergillus Infections In Transplant Recipientmentioning

confidence: 99%

AspergillusInfections in Transplant Recipients

2005

View full text Add to dashboard Cite

Aspergillus infections are occurring with an increasing frequency in transplant recipients. Notable changes in the epidemiologic characteristics of this infection have occurred; these include a change in risk factors and later onset of infection. Management of invasive aspergillosis continues to be challenging, and the mortality rate, despite the use of newer antifungal agents, remains unacceptably high. Performing molecular studies to discern new targets for antifungal activity, identifying signaling pathways that may be amenable to immunologic interventions, assessing combination regimens of antifungal agents or combining antifungal agents with modulation of the host defense mechanisms, and devising diagnostic assays that can rapidly and reliably diagnose infections represent areas for future investigations that may lead to further improvement in outcomes

show abstract

“…flavus has been reported as a cause of both native and prosthetic valve endocarditis, which is occasionally a manifestation of disseminated aspergillosis (Demaria et al, 2000;Rao & Saha, 2000;Irles et al, 2004). Occasional cases occur in patients with no overt risk factors (Kennedy et al, 1998;Khan et al, 1995).…”

Section: Endocarditis and Pericarditismentioning

confidence: 99%

Aspergillus flavus: human pathogen, allergen and mycotoxin producer

et al. 2007

View full text Add to dashboard Cite

Aspergillus infections have grown in importance in the last years. However, most of the studies have focused on Aspergillus fumigatus, the most prevalent species in the genus. In certain locales and hospitals, Aspergillus flavus is more common in air than A. fumigatus, for unclear reasons. After A. fumigatus, A. flavus is the second leading cause of invasive aspergillosis and it is the most common cause of superficial infection. Experimental invasive infections in mice show A. flavus to be 100-fold more virulent than A. fumigatus in terms of inoculum required. Particularly common clinical syndromes associated with A. flavus include chronic granulomatous sinusitis, keratitis, cutaneous aspergillosis, wound infections and osteomyelitis following trauma and inoculation. Outbreaks associated with A. flavus appear to be associated with single or closely related strains, in contrast to those associated with A. fumigatus. In addition, A. flavus produces aflatoxins, the most toxic and potent hepatocarcinogenic natural compounds ever characterized. Accurate species identification within Aspergillus flavus complex remains difficult due to overlapping morphological and biochemical characteristics, and much taxonomic and population genetics work is necessary to better understand the species and related species. The flavus complex currently includes 23 species or varieties, including two sexual species, Petromyces alliaceus and P. albertensis. The genome of the highly related Aspergillus oryzae is completed and available; that of A. flavus in the final stages of annotation. Our understanding of A. flavus lags far behind that of A. fumigatus. Studies of the genomics, taxonomy, population genetics, pathogenicity, allergenicity and antifungal susceptibility of A. flavus are all required.

show abstract

MEDICAL MANAGEMENT OFASPERGILLUS FLAVUSENDOCARDITIS

Cited by 29 publications

References 4 publications

Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation

Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation

AspergillusInfections in Transplant Recipients

Aspergillus flavus: human pathogen, allergen and mycotoxin producer

Contact Info

Product

Resources

About